Ich stimme der Verwendung von Cookies zu. Auch wenn ich diese Website weiter nutze, gilt dies als Zustimmung.

Bitte lesen und akzeptieren Sie die Datenschutzinformation und Cookie-Informationen, damit Sie unser Angebot weiter nutzen können. Natürlich können Sie diese Einwilligung jederzeit widerrufen.






21st Austria weekly - Marinomed, Wolford, Vienna Stock Exchange (20/05/2022)

22.05.2022

Marinomed: Austrian Marinomed Biotech AG announced the execution of a license agreement with Procter & Gamble Company (NYSE: PG), hereinafter referred to as "P&G", for the United States of America regarding the Carragelose® products of Marinomed, which are protected by various patents that cover the use of iota-carrageenan for the treatment of diseases caused by or associated with an infection by a respiratory virus. P&G will take the necessary steps to obtain regulatory approval for the commercialization of the Carragelose® products in the United States of America. Marinomed is responsible for the technology transfer, i.e., providing P&G with the data required for obtaining regulatory approval and the intellectual property rights (patents, know-how) in the form of a license for the commercialization of the Carragelose® products in the United States of America. Under the terms of the agreement and depending on the achievement of specified regulatory and commercial milestones, Marinomed is eligible to receive milestone payments as well as royalties on Carragelose® sales in the United States of America.
Marinomed Biotech: weekly performance: 8.70%

Wolford: Bodywear company Wolford AG further postpones the publication of the audited annual financial statements as of 31 December 31 and the audited consolidated financial statements as of 31 December 2021. The audited annual financial statements and the audited consolidated financial statements are to be published no later than 17 June 2022. The Annual General Meeting for the 2021 financial year will be postponed. A new date will be announced as soon as possible. A positive EBITDA is expected for the 2021 financial year. The previously communicated outlook of a positive EBIT cannot be sustained.
Wolford: weekly performance: 0.78%

Vienna Stock Exchange: Vienna ESG Segment enhances transparency in the growing offering of ESG bonds. The new rulebook with mandatory inclusion and follow-up obligations for sustainable bonds enters into force today. It is based on internationally established standards (Principles of the International Capital Market Association). A second party opinion is required from new issuers, and ongoing disclosures are strengthened. The "Vienna ESG Segment" offers more visibility to companies that raise funds for green or social projects and meet the strict listing and follow-up requirements. 
ATX TR: weekly performance: 3.86%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (20/05/2022)


Partners









latest 21st Austria

21st Austria weekly - Marinomed, Wolford, Vienna Stock Exchange (20/05/2022)


22.05.2022, 2509 Zeichen



Marinomed: Austrian Marinomed Biotech AG announced the execution of a license agreement with Procter & Gamble Company (NYSE: PG), hereinafter referred to as "P&G", for the United States of America regarding the Carragelose® products of Marinomed, which are protected by various patents that cover the use of iota-carrageenan for the treatment of diseases caused by or associated with an infection by a respiratory virus. P&G will take the necessary steps to obtain regulatory approval for the commercialization of the Carragelose® products in the United States of America. Marinomed is responsible for the technology transfer, i.e., providing P&G with the data required for obtaining regulatory approval and the intellectual property rights (patents, know-how) in the form of a license for the commercialization of the Carragelose® products in the United States of America. Under the terms of the agreement and depending on the achievement of specified regulatory and commercial milestones, Marinomed is eligible to receive milestone payments as well as royalties on Carragelose® sales in the United States of America.
Marinomed Biotech: weekly performance: 8.70%

Wolford: Bodywear company Wolford AG further postpones the publication of the audited annual financial statements as of 31 December 31 and the audited consolidated financial statements as of 31 December 2021. The audited annual financial statements and the audited consolidated financial statements are to be published no later than 17 June 2022. The Annual General Meeting for the 2021 financial year will be postponed. A new date will be announced as soon as possible. A positive EBITDA is expected for the 2021 financial year. The previously communicated outlook of a positive EBIT cannot be sustained.
Wolford: weekly performance: 0.78%

Vienna Stock Exchange: Vienna ESG Segment enhances transparency in the growing offering of ESG bonds. The new rulebook with mandatory inclusion and follow-up obligations for sustainable bonds enters into force today. It is based on internationally established standards (Principles of the International Capital Market Association). A second party opinion is required from new issuers, and ongoing disclosures are strengthened. The "Vienna ESG Segment" offers more visibility to companies that raise funds for green or social projects and meet the strict listing and follow-up requirements. 
ATX TR: weekly performance: 3.86%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (20/05/2022)



BSN Podcasts
Christian Drastil: Wiener Börse Plausch

Wiener Börse Party #777: ATX schwächer, Palfinger und RWT glauben an sich und am Montag kommt The One and Only




 

Bildnachweis

Aktien auf dem Radar:Warimpex, RBI, Andritz, Immofinanz, CA Immo, Addiko Bank, Agrana, Frequentis, Pierer Mobility, AT&S, Cleen Energy, FACC, Lenzing, Linz Textil Holding, SW Umwelttechnik, EuroTeleSites AG, Oberbank AG Stamm, Zumtobel, Kapsch TrafficCom, Amag, Erste Group, EVN, Flughafen Wien, OMV, Österreichische Post, S Immo, Telekom Austria, Uniqa, VIG, Wienerberger.


Random Partner

iMaps Capital
iMaps Capital ist ein Wertpapier- und Investmentunternehmen mit Schwerpunkt auf aktiv verwaltete Exchange Traded Instruments (ETI). iMaps, mit Sitz auf Malta und Cayman Islands, positioniert sich als Private Label Anbieter und fungiert als Service Provider für Asset Manager und Privatbanken, welche  ETIs zur raschen und kosteneffizienten Emission eines börsegehandelten Investment Produktes nutzen wollen.

>> Besuchen Sie 68 weitere Partner auf boerse-social.com/partner


Useletter

Die Useletter "Morning Xpresso" und "Evening Xtrakt" heben sich deutlich von den gängigen Newslettern ab. Beispiele ansehen bzw. kostenfrei anmelden. Wichtige Börse-Infos garantiert.

Newsletter abonnieren

Runplugged

Infos über neue Financial Literacy Audio Files für die Runplugged App
(kostenfrei downloaden über http://runplugged.com/spreadit)

per Newsletter erhalten